IDE Voya management lays out key infrastructure sector investment priorities in its latest quarterly earnings release Inovio Pharmaceuticals INO Stock Entry Opportunity Breakdown Q4 2025 EPS Beats Forecasts Spruce Biosciences SPRB Stock Manual Trade Technical Weakness 20260420 NTLA Intellia Therapeutics tops Q4 2025 EPS estimates posts 169 percent yearoveryear revenue growth as shares edge slightly lower